Temporal changes in soluble angiotensin-converting enzyme 2 associated with metabolic health, body composition, and proteome dynamics during a weight loss diet intervention: a randomized trial with implications for the COVID-19 pandemic.
Nicholas CauwenberghsMary M PrunickiFrantišek SabovčikDalia PerelmanKévin ContrepoisXiao LiMichael Paul SnyderKari Christine NadeauTatiana KuznetsovaFrancois HaddadChristopher D GardnerPublished in: The American journal of clinical nutrition (2021)
Decrease in sACE2 during a weight loss diet intervention was associated with improvements in metabolic health, fat mass, and markers of angiotensin peptide metabolism, hepatic and vascular injury, renal function, chronic inflammation, and oxidative stress. Our findings may improve the risk stratification, prevention, and management of cardiometabolic complications.This trial was registered at clinicaltrials.gov as NCT01826591.
Keyphrases
- weight loss
- body composition
- angiotensin converting enzyme
- oxidative stress
- bariatric surgery
- angiotensin ii
- roux en y gastric bypass
- public health
- randomized controlled trial
- healthcare
- gastric bypass
- resistance training
- bone mineral density
- mental health
- clinical trial
- adipose tissue
- health information
- physical activity
- weight gain
- phase iii
- type diabetes
- glycemic control
- obese patients
- phase ii
- health promotion
- dna damage
- induced apoptosis
- diabetic rats
- drug induced
- open label
- skeletal muscle
- signaling pathway
- postmenopausal women